Table 1.

Clinical, Cytogenetic, and Antibody Staining Data of the 14 Leukemia Patients

CaseSexLeukocyte CountBlast %*FABImmunophenotypeCytogeneticsReactivity With
(×109/L)G289-781
5.1 99 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
12.0 66 L1 Early pre-B ALL 57,XY,[no t(1; 19)] − 
36.1 95 L1 Pre-B ALL 56,XX,[no t(1; 19)] − 
74.1 95 L1 Pre-B ALL t(1; 19)(q23; p13) 
248.1 95 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
159.2 98 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
19.7 97 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
193.0 98 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
402.0 94 L1 T-ALL 46,XY,[no t(1; 19)] − 
10 395.5 99 L1 Early pre-B ALL 46,XX,[no t(1; 19)] − 
11 19.0 12  Myeloid 46,XY, t(9; 22)(q34; q11) − 
12 97.3 91 L2 Early pre-B ALL 39,XX,[no t(1; 19)] − 
13 531.3 98 L1 Pre-B 46,XX, t(4; 11)(q21; q23) − 
14 496.0 97 L2 T-ALL 46,XY, t(11; 19)(q23; p13.3) − 
CaseSexLeukocyte CountBlast %*FABImmunophenotypeCytogeneticsReactivity With
(×109/L)G289-781
5.1 99 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
12.0 66 L1 Early pre-B ALL 57,XY,[no t(1; 19)] − 
36.1 95 L1 Pre-B ALL 56,XX,[no t(1; 19)] − 
74.1 95 L1 Pre-B ALL t(1; 19)(q23; p13) 
248.1 95 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
159.2 98 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
19.7 97 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
193.0 98 L1 Pre-B ALL der(19)t(1; 19)(q23; p13) 
402.0 94 L1 T-ALL 46,XY,[no t(1; 19)] − 
10 395.5 99 L1 Early pre-B ALL 46,XX,[no t(1; 19)] − 
11 19.0 12  Myeloid 46,XY, t(9; 22)(q34; q11) − 
12 97.3 91 L2 Early pre-B ALL 39,XX,[no t(1; 19)] − 
13 531.3 98 L1 Pre-B 46,XX, t(4; 11)(q21; q23) − 
14 496.0 97 L2 T-ALL 46,XY, t(11; 19)(q23; p13.3) − 

Abbreviation: FAB, French-American-British Cooperative Group Classification.

*

Bone marrow blast percentage.

Results of antibody reactivity by flow cytometry, immunohistochemistry, and Western blotting.

Case of chronic myelocytic leukemia.

Close Modal

or Create an Account

Close Modal
Close Modal